These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 36324078)
41. Autoantibody profile in a Malaysian cohort of chronic inflammatory demyelinating polyneuropathy. Tan CY; Goh KJ; Oh AW; Devaux J; Shahrizaila N Neuromuscul Disord; 2022 Mar; 32(3):255-262. PubMed ID: 35183410 [TBL] [Abstract][Full Text] [Related]
42. Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement. Kokubun N; Sada T; Yuki N; Okabe M; Hirata K Eur Neurol; 2013; 70(1-2):65-9. PubMed ID: 23796651 [TBL] [Abstract][Full Text] [Related]
43. An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy. Kapoor M; Compton L; Rossor A; Hutton E; Manji H; Lunn M; Reilly M; Carr A J Peripher Nerv Syst; 2021 Dec; 26(4):461-468. PubMed ID: 34637194 [TBL] [Abstract][Full Text] [Related]
44. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895 [TBL] [Abstract][Full Text] [Related]
45. Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Merkies ISJ; van Schaik IN; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; J Peripher Nerv Syst; 2022 Jun; 27(2):159-165. PubMed ID: 35266243 [TBL] [Abstract][Full Text] [Related]
46. Association between chronic inflammatory demyelinating polyneuropathy and gastrointestinal malignancies. Malik A; Berry R; Fung BM; Tabibian JH Clin J Gastroenterol; 2021 Feb; 14(1):1-13. PubMed ID: 33146871 [TBL] [Abstract][Full Text] [Related]
47. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. Rajabally YA; Afzal S J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098 [TBL] [Abstract][Full Text] [Related]
48. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis. Racosta JM; Sposato LA; Kimpinski K Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063 [TBL] [Abstract][Full Text] [Related]
49. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749 [TBL] [Abstract][Full Text] [Related]
51. [Autoantibodies in Chronic Inflammatory Demyelinating Polyneuropathy]. Koga M Brain Nerve; 2018 Apr; 70(4):395-403. PubMed ID: 29632287 [TBL] [Abstract][Full Text] [Related]
52. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. van Dijk GW; Notermans NC; Franssen H; Wokke JH J Neurol; 1999 Dec; 246(12):1134-9. PubMed ID: 10653304 [TBL] [Abstract][Full Text] [Related]
53. Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy. Lucke IM; Wieske L; van der Kooi AJ; van Schaik IN; Eftimov F; Verhamme C J Peripher Nerv Syst; 2019 Jun; 24(2):174-179. PubMed ID: 31090121 [TBL] [Abstract][Full Text] [Related]
54. [Chronic inflammatory demyelinating polyneuropathy followed by systemic lupus erythematosus and Sjögren syndrome: a case report]. Hatano T; Fukuda M; Shiotsuki H; Miwa H; Urabe T; Mizuno Y Rinsho Shinkeigaku; 2006 Mar; 46(3):203-9. PubMed ID: 16642931 [TBL] [Abstract][Full Text] [Related]
55. Chronic inflammatory demyelinating polyneuropathy following COVID-19 vaccination: a case report and literature review. Bahramy MA; Hashempour Z; Shahriarirad R BMC Neurol; 2024 Jul; 24(1):262. PubMed ID: 39075432 [TBL] [Abstract][Full Text] [Related]
57. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin. Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265 [TBL] [Abstract][Full Text] [Related]
58. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922 [TBL] [Abstract][Full Text] [Related]
59. Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy. Opala AR; Kennedy K; Baker SK Can J Neurol Sci; 2020 Jul; 47(4):531-537. PubMed ID: 32279669 [TBL] [Abstract][Full Text] [Related]
60. Chronic inflammatory demyelinating polyneuropathy: a rare cause of falls. Saad TC; Pickrell WO; Payne G; Hamandi K BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31796460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]